What's the Problem?

Almost 50% of the world population does not have access to basic diagnosis. This number goes down to 20% in low- and middle- income countries. There are two ways to diagnose infectious diseases: either by detecting pathogens or antibodies. Pathogen detection may not be adequate when not done at the beginning of the infection, as this can cause false negatives, while antibody tests can identify both active and past infections in a wide time frame, expanding the possibility to accurately treat a person. Currently, antibody testing uses recombinant proteins as antigens. The problem with these proteins is that they are biologically produced, which is complex and not cost-affordable. This solution doesn't scale.

How are they Solving it?

At Ubique, we have developed a Platform, improved to shorten R&D development time, to design synthetic peptides that replace recombinant proteins in antibody detection tests. Our approach is based on the synthetic peptide’s library design using immunoinformatic, efficacy detection testing against patients’ sera, and peptide chemical synthesis in bulk. The obtained peptides have the unique characteristics of being highly specific, sensitive, and thermostable. They are also ready to be included within most commercially available tests. Our products provide efficient multiplex diagnostics, allowing us to create specific Solutions to detect multiple infectious diseases at the same time, saving both time and money, while reducing the diagnostic gap in the world.

Go to their website

Next Startup

SphereBio

Go back to portfolio